Granted Patent B2

US 12,441,728 · App. 18/480,925 · Granted Oct 14, 2025

Inventor: Stéphane Dorich (Pointe-Claire, CA)

Assignee: Ventus Therapeutics U.S., Inc.

C07D471/04A61K31/501A61K31/502A61K31/5025A61K31/5377C07D405/12C07D491/048C07D495/04C07D519/00

Abstract

Claims (17)

1. A compound of Formula (II):

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

Y is phenyl independently substituted with one or more C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, halo, cyano, or —R 4 OR 5 , wherein at least one substitution is substituted at the para-position of the phenyl ring;

R 1 is

5- to 9- membered heteroaryl optionally substituted with one or more halo, —R 4 OR 5 , an optionally substituted 3- to 8-membered heterocycloalkyl, an optionally substituted C 5 -C 10 aryl, or an optionally substituted 5- to 9-membered heteroaryl;

R 2 and R 3 , together with the atoms to which they are attached, form a 5- to 9-membered heteroaryl optionally substituted with one or more R 2a ;

R 2a is hydrogen, C 1 -C 6 alkyl, halo or C 1 -C 6 haloalkyl;

R 4 is absent, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl; and

R 5 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein Y is phenyl substituted at the para-position of the phenyl ring with C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, halo, cyano, or —R 4 OR 5 .

3. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein Y is phenyl independently substituted with two C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, halo, cyano, or —R 4 OR 5 , wherein at least one substitution is substituted at the para-position of the phenyl ring.

4. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein R 5 is hydrogen.

5. The compound of claim 1 , wherein R 2 and R 3 are joined to form

to provide a compound of Formula (II-h)

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof; wherein R 2a is H.

6. An isotopic derivative of the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof.

7. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, and one or more pharmaceutically acceptable carriers.

Assignments (2)

Continuity (4)

References Cited (400)